Compare McKesson Corporation (MCK) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Oklo Inc — how do they compare? McKesson Corporation trades at $823.64 (market cap $97.35B), while Oklo Inc trades at $43.88 (market cap $7.22B). The key difference: McKesson Corporation is far larger — about 13.5× Oklo Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| MCK | OKLO | |
|---|---|---|
Market Cap | $97.35B | $7.22B |
Sector | Health | Technology |
52-Week High | $995.69 | $174.14 |
52-Week Low | $659.01 | $41.11 |
Enterprise Value | $101.98B | $5.02B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
OKLO trades at $41.51, down 42% year-to-date amid regulatory uncertainty and recent stock dilution. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but fundamentals remain weak with negative earnings and cash flow. Recent news highlights progress on nuclear projects but regulatory hurdles persist.
OKLO presents high-risk/high-reward potential with significant upside to analyst targets but faces execution risks and negative profitability. The stock's bearish technical signals contrast with bullish long-term nuclear energy thesis. Regulatory approvals and Meta partnership execution remain critical catalysts for valuation recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
